journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/29328862/what-happens-when-proton-meets-randomization-is-there-a-future-for-proton-therapy
#1
Feng-Ming Spring Kong
No abstract text is available yet for this article.
January 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29328861/radiofrequency-ablation-versus-stereotactic-body-radiotherapy-for-localized-hepatocellular-carcinoma-in-nonsurgically-managed-patients-analysis-of-the-national-cancer-database
#2
Devalkumar J Rajyaguru, Andrew J Borgert, Angela L Smith, Reggie M Thomes, Patrick D Conway, Thorvardur R Halfdanarson, Mark J Truty, A Nicholas Kurup, Ronald S Go
Purpose Data that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data for these treatment modalities, we aimed to compare the effectiveness of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) by using the National Cancer Database. Methods We conducted an observational study to compare the effectiveness of RFA versus SBRT in nonsurgically managed patients with stage I or II HCC...
January 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29328860/quality-of-life-from-canadian-cancer-trials-group-ma-17r-a-randomized-trial-of-extending-adjuvant-letrozole-to-10-years
#3
Julie Lemieux, Michael D Brundage, Wendy R Parulekar, Paul E Goss, James N Ingle, Kathleen I Pritchard, Paul Celano, Hyman Muss, Julie Gralow, Kathrin Strasser-Weippl, Kate Whelan, Dongsheng Tu, Timothy J Whelan
Purpose MA.17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and menopause-specific QOL (MENQOL; four symptom domains) at baseline and every 12 months up to 60 months...
January 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29320312/targeted-therapy-for-advanced-solid-tumors-on-the-basis-of-molecular-profiles-results-from-mypathway-an-open-label-phase-iia-multiple-basket-study
#4
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock
Purpose Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer. These molecular alterations may occur in other tumor types for which the efficacy of targeted therapy remains unclear. The MyPathway study evaluates the efficacy and safety of selected targeted therapies in tumor types that harbor relevant genetic alterations but are outside of current labeling for these treatments. Methods MyPathway ( ClinicalTrials.gov identifier: NCT02091141) is a multicenter, nonrandomized, phase IIa multiple basket study...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29320311/development-and-validation-of-a-risk-prediction-model-for-acute-kidney-injury-after-the-first-course-of-cisplatin
#5
Shveta S Motwani, Gearoid M McMahon, Benjamin D Humphreys, Ann H Partridge, Sushrut S Waikar, Gary C Curhan
Purpose Cisplatin-associated acute kidney injury (C-AKI) is common. We sought to develop and validate a predictive model for C-AKI after the first course of cisplatin. Methods Clinical and demographic data were collected on patients who received cisplatin between 2000 and 2016 at two cancer centers. C-AKI was defined as a 0.3 mg/dL rise in serum creatinine within 14 days of receiving cisplatin. Using multivariable logistic regression models with C-AKI as the primary outcome, we created a scoring model from the development cohort (DC) and tested it in the validation cohort (VC)...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29315015/tumor-specific-t-cells-engineered-to-overcome-tumor-immune-evasion-induce-clinical-responses-in-patients-with-relapsed-hodgkin-lymphoma
#6
Catherine M Bollard, Tamara Tripic, Conrad Russell Cruz, Gianpietro Dotti, Stephen Gottschalk, Vicky Torrano, Olga Dakhova, George Carrum, Carlos A Ramos, Hao Liu, Meng-Fen Wu, Andrea N Marcogliese, Cecilia Barese, Youli Zu, Daniel Y Lee, Owen O'Connor, Adrian P Gee, Malcolm K Brenner, Helen E Heslop, Cliona M Rooney
Purpose Transforming growth factor-β (TGF-β) production in the tumor microenvironment is a potent and ubiquitous tumor immune evasion mechanism that inhibits the expansion and function of tumor-directed responses; therefore, we conducted a clinical study to discover the effects of the forced expression of a dominant-negative TGF-β receptor type 2 (DNRII) on the safety, survival, and activity of infused tumor-directed T cells. Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 doses of between 2 × 107 and 1...
January 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29309250/cost-effectiveness-of-gene-expression-profile-testing-in-community-practice
#7
Young Chandler, Clyde B Schechter, Jinani Jayasekera, Aimee Near, Suzanne C O'Neill, Claudine Isaacs, Charles E Phelps, G Thomas Ray, Tracy A Lieu, Scott Ramsey, Jeanne S Mandelblatt
Purpose Gene expression profile (GEP) testing can support chemotherapy decision making for patients with early-stage, estrogen receptor-positive, human epidermal growth factor 2-negative breast cancers. This study evaluated the cost effectiveness of one GEP test, Onco type DX (Genomic Health, Redwood City, CA), in community practice with test-eligible patients age 40 to 79 years. Methods A simulation model compared 25-year societal incremental costs and quality-adjusted life-years (QALYs) of community Onco type DX use from 2005 to 2012 versus usual care in the pretesting era (2000 to 2004)...
January 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29309249/cabozantinib-a-new-standard-of-care-for-patients-with-advanced-renal-cell-carcinoma-and-bone-metastases-subgroup-analysis-of-the-meteor-trial
#8
Bernard Escudier, Thomas Powles, Robert J Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stephane Oudard, Frederic Rolland, Piotr Tomczak, Daniel Castellano, Leonard J Appleman, Harry Drabkin, Daniel Vaena, Steven Milwee, Jillian Youkstetter, Julie C Lougheed, Sergio Bracarda, Toni K Choueiri
Purpose Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascular endothelial growth factor receptor-targeted therapy in the phase III METEOR trial. Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR...
January 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29303626/guarantee-time-bias-and-benefits-of-surgery-for-pleural-mesothelioma
#9
Steven E Vogl
No abstract text is available yet for this article.
January 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29303625/reply-to-s-e-vogl
#10
David B Nelson, David C Rice, Jiangong Niu, Reza J Mehran, Boris Sepesi
No abstract text is available yet for this article.
January 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29303624/optimization-of-risk-stratification-in-localized-prostate-cancer
#11
Alicia Katherine Morgans
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
January 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29300620/tp53-germline-variations-influence-the-predisposition-and-prognosis-of-b-cell-acute-lymphoblastic-leukemia-in-children
#12
Maoxiang Qian, Xueyuan Cao, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Yunfeng Dai, Andrew Carroll, Nyla A Heerema, Hui Zhang, Takaya Moriyama, Julie M Gastier-Foster, Heng Xu, Elizabeth Raetz, Eric Larsen, Naomi Winick, W Paul Bowman, Paul L Martin, Elaine R Mardis, Robert Fulton, Gerard Zambetti, Michael Borowitz, Brent Wood, Kim E Nichols, William L Carroll, Ching-Hon Pui, Charles G Mullighan, William E Evans, Stephen P Hunger, Mary V Relling, Mignon L Loh, Jun J Yang
Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900...
January 4, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29298118/circulating-tumor-dna-guides-prognosis-in-metastatic-triple-negative-breast-cancer
#13
Andjelija Zivanovic Bujak, Sarah-Jane Dawson
No abstract text is available yet for this article.
January 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29298117/association-of-cell-free-dna-tumor-fraction-and-somatic-copy-number-alterations-with-survival-in-metastatic-triple-negative-breast-cancer
#14
Daniel G Stover, Heather A Parsons, Gavin Ha, Samuel S Freeman, William T Barry, Hao Guo, Atish D Choudhury, Gregory Gydush, Sarah C Reed, Justin Rhoades, Denisse Rotem, Melissa E Hughes, Deborah A Dillon, Ann H Partridge, Nikhil Wagle, Ian E Krop, Gad Getz, Todd R Golub, J Christopher Love, Eric P Winer, Sara M Tolaney, Nancy U Lin, Viktor A Adalsteinsson
Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC...
January 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293390/reply-to-e-ramos-et-al
#15
Kevin S Hughes
No abstract text is available yet for this article.
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293389/genetic-testing-multiple-problems-to-solve
#16
Erica Ramos, Joy Larsen Haidle
No abstract text is available yet for this article.
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293388/population-based-genetic-testing-for-brca1-and-brca2
#17
Steven Narod, Mohammad R Akbari
No abstract text is available yet for this article.
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293387/reply-to-s-nakamura-et-al-and-s-narod-et-al
#18
Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko
No abstract text is available yet for this article.
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293386/bayesian-adaptive-randomization-trial-of-passive-scattering-proton-therapy-and-intensity-modulated-photon-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer
#19
Zhongxing Liao, J Jack Lee, Ritsuko Komaki, Daniel R Gomez, Michael S O'Reilly, Frank V Fossella, George R Blumenschein, John V Heymach, Ara A Vaporciyan, Stephen G Swisher, Pamela K Allen, Noah Chan Choi, Thomas F DeLaney, Stephen M Hahn, James D Cox, Charles S Lu, Radhe Mohan
Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non-small-cell lung cancer (NSCLC). We hypothesized that PSPT exposes less lung tissue to radiation than IMRT and thereby reduces toxicity without compromising tumor control. The primary end points were grade ≥ 3 radiation pneumonitis (RP) and local failure (LF). Patients and Methods Eligible patients had stage IIB to IIIB NSCLC (or stage IV NSCLC with a single brain metastasis or recurrent lung or mediastinal disease after surgery) who were candidates for concurrent chemoradiation therapy...
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29293385/adaptation-of-genetic-counseling-according-to-an-individual-s-literacy-regarding-genomics
#20
Sho Nakamura, Hiroto Narimatsu
No abstract text is available yet for this article.
January 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"